| Title |
Combined Analysis of Phase III Trials Evaluating [99mTc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma
|
|---|---|
| Published in |
Annals of Surgical Oncology, October 2012
|
| DOI | 10.1245/s10434-012-2612-z |
| Pubmed ID | |
| Authors |
Vernon K. Sondak, Dennis W. King, Jonathan S. Zager, Schlomo Schneebaum, Julian Kim, Stanley P. L. Leong, Mark B. Faries, Bruce J. Averbook, Steve R. Martinez, Christopher A. Puleo, Jane L. Messina, Lori Christman, Anne M. Wallace |
| Abstract |
[(99m)Tc]Tilmanocept is a CD206 receptor-targeted radiopharmaceutical designed for sentinel lymph node (SLN) identification. Two nearly identical nonrandomized phase III trials compared [(99m)Tc]tilmanocept to vital blue dye. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| United States | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Unknown | 60 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 21% |
| Other | 12 | 20% |
| Researcher | 8 | 13% |
| Student > Doctoral Student | 7 | 11% |
| Student > Master | 5 | 8% |
| Other | 7 | 11% |
| Unknown | 9 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 51% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Chemistry | 3 | 5% |
| Agricultural and Biological Sciences | 3 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Other | 6 | 10% |
| Unknown | 11 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2016.
All research outputs
#2,062,899
of 22,696,971 outputs
Outputs from Annals of Surgical Oncology
#470
of 6,425 outputs
Outputs of similar age
#14,497
of 172,454 outputs
Outputs of similar age from Annals of Surgical Oncology
#3
of 51 outputs
Altmetric has tracked 22,696,971 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,425 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,454 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.